C. Decatur

发表

Punctuated evolution of canonical genomic aberrations in uveal melanoma

Michael A. Durante, A. Bowcock, J. Harbour, 2018, Nature Communications.

C. Decatur, R. Lynch, W. Stamer, 2008, PLoS biology.

Single-cell analysis reveals new evolutionary complexity in uveal melanoma

Michael A. Durante, J. Harbour, S. Kurtenbach, 2020, Nature Communications.

2-Deoxy-GlucoseDownregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation , Induction of Endoplasmic Reticulum Stress , and GSK 3 b Activation

T. Lampidis, C. Decatur, J. Merchan, 2016 .

2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3β Activation

T. Lampidis, C. Decatur, J. Merchan, 2015, Molecular Cancer Therapeutics.

Pharmacotherapy for radiation retinopathy

A. Markoe, C. Decatur, T. Murray, 2010 .

Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors.

W. Feuer, T. Lampidis, C. Decatur, 2012, Investigative ophthalmology & visual science.

Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LHBETATAG retinal tumors

W. Feuer, T. Lampidis, C. Decatur, 2011, Clinical ophthalmology.

Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment

Nisha V. Shah, A. Markoe, W. Feuer, 2013, Clinical ophthalmology.

Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.

A. Bowcock, J. Harbour, N. Garg, 2016, JAMA ophthalmology.

BAP1 Loss Promotes Suppressive Tumor Immune Microenvironment via Upregulation of PROS1 in Class 2 Uveal Melanomas

Anthony M. Cruz, J. Licht, K. Smalley, 2022, Cancers.

PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma

Stefan Kurtenbach, Martine J Jager, S. Kurtenbach, 2016, Clinical Cancer Research.

Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis

Michael M. Vigoda, H. Flynn, A. Moshfeghi, 2010, Clinical ophthalmology.

BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas

Karam A. Alawa, J. Harbour, Matthew G. Field, 2019, Clinical Cancer Research.

Single-cell analysis reveals new evolutionary complexity in uveal melanoma

Michael A. Durante, J. Harbour, L. Feun, 2020, Nature Communications.

Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas

Michael A. Durante, A. Bowcock, J. Harbour, 2016, Oncotarget.

Intravitreal and Subconjunctival Melphalan for Retinoblastoma in Transgenic Mice

Nisha V. Shah, C. Decatur, T. Murray, 2014, Journal of ophthalmology.

Impact of Genetic Ancestry on Prognostic Biomarkers in Uveal Melanoma

E. Martin, J. Harbour, J. Harbour, 2020, Cancers.

Punctuated evolution of canonical genomic aberrations in uveal melanoma

A. Bowcock, J. Harbour, Matthew G. Field, 2018, Nature Communications.

Genomic evolution of uveal melanoma arising in ocular melanocytosis

Sander R. Dubovy, Michael A. Durante, K. Covington, 2019, Cold Spring Harbor molecular case studies.

Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LHBETATAG retinal tumors

W. Scott, T. Lampidis, L. Nathanson, 2012, Clinical ophthalmology.

Microincisional vitrectomy for retinal detachment in I-125 brachytherapy-treated patients with posterior uveal malignant melanoma

A. Markoe, C. Decatur, T. Murray, 2013, Clinical ophthalmology.

Intraocular Metastasis in Unilateral Multifocal Uveal Melanoma Without Melanocytosis or Germline BAP1 Mutations.

Sander R. Dubovy, Michael A. Durante, J. Harbour, 2019, JAMA ophthalmology.

Intraocular Dissemination of Uveal Melanoma Cells Following Radiotherapy: Evolving Management Over the Past Decade.

Sander R. Dubovy, J. Harbour, C. Decatur, 2019, Ophthalmic surgery, lasers & imaging retina.

Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma.

J. Harbour, C. Decatur, B. Tarlan, 2018, American journal of ophthalmology.

RB1 loss triggers dependence on ESRRG in retinoblastoma

Michael A. Durante, J. Harbour, Matthew G. Field, 2021, bioRxiv.

Abstract 4642: Combined glycolytic inhibition and anti-vascular treatment in retinoblastoma: Novel strategy for tumor control avoids chemotherapy

T. Lampidis, C. Decatur, T. Murray, 2012 .

Analytical Validation and Performance of a 7-Gene Next-Generation Sequencing Panel in Uveal Melanoma

K. Covington, J. Harbour, F. Monzon, 2020, Ocular Oncology and Pathology.

2-DEOXY-GLUCOSE DOWN REGULATES ENDOTHELIAL AKT AND ERK VIA INTERFERENCE WITH N-LINKED GLYCOSYLATION, INDUCTION OF ENDOPASMIC RETICULUM STRESS AND GSK-3 β ACTIVATION INHIBITION OF ENDOTHELIAL AKT AND ERK BY

T. Lampidis, C. Decatur, Christina L Decatur, 2015 .